These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. Shen JK; Cote GM; Gao Y; Choy E; Mankin HJ; Hornicek FJ; Duan Z Sci Rep; 2016 Apr; 6():25239. PubMed ID: 27125524 [TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841 [TBL] [Abstract][Full Text] [Related]
8. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier. Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495 [TBL] [Abstract][Full Text] [Related]
9. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935 [TBL] [Abstract][Full Text] [Related]
10. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction. Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620 [TBL] [Abstract][Full Text] [Related]
11. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449 [TBL] [Abstract][Full Text] [Related]
12. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798 [TBL] [Abstract][Full Text] [Related]
13. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition. Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465 [No Abstract] [Full Text] [Related]
14. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690 [TBL] [Abstract][Full Text] [Related]
15. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009 [TBL] [Abstract][Full Text] [Related]
16. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer. Zöllner SK; Rössig C; Toretsky JA Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104 [TBL] [Abstract][Full Text] [Related]
17. Targeting epigenetics in sarcomas through EZH2 inhibition. Italiano A J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965 [TBL] [Abstract][Full Text] [Related]
18. ATR Is a Therapeutic Target in Synovial Sarcoma. Jones SE; Fleuren EDG; Frankum J; Konde A; Williamson CT; Krastev DB; Pemberton HN; Campbell J; Gulati A; Elliott R; Menon M; Selfe JL; Brough R; Pettitt SJ; Niedzwiedz W; van der Graaf WTA; Shipley J; Ashworth A; Lord CJ Cancer Res; 2017 Dec; 77(24):7014-7026. PubMed ID: 29038346 [TBL] [Abstract][Full Text] [Related]
19. Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2). Changchien YC; Tátrai P; Papp G; Sápi J; Fónyad L; Szendrői M; Pápai Z; Sápi Z J Transl Med; 2012 Oct; 10():216. PubMed ID: 23110793 [TBL] [Abstract][Full Text] [Related]
20. PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease. Kadoch C; Copeland RA; Keilhack H Biochemistry; 2016 Mar; 55(11):1600-14. PubMed ID: 26836503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]